NRG1 and breast carcinoma: Furthermore, the analysis of the ERBB3 ligand NRG1 unveiled very low levels in breast cancer tissue compared to normal specimens, with minimal differences among clinical and molecular breast cancer subtypes (Supplementary Figure S1a,b).